A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Key facts

Study ID

NCT06220604

Run by

Janssen Research & Development, LLC

People needed

731

Starts

2024-03-09

Expected to finish

2027-09-20

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
• Total psoriasis area and severity index (PASI) >=12 at screening and baseline
• Total investigator global assessment (IGA) >=3 at screening and baseline
• Candidate for phototherapy or systemic treatment for plaque psoriasis

You may not qualify if…

• Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
• Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib or to any of the excipients or components of the study intervention
• Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study

Where it is running

• California Dermatology & Clinical Research Institute — Encinitas, California, United States
• T Joseph Raoof Md Inc — Encino, California, United States
• UCSF Fresno — Fresno, California, United States
• University of California Los Angeles - Division of Dermatology — Los Angeles, California, United States
• Wallace Medical Group, Inc — Los Angeles, California, United States
• Dermatologist Medical Group of North County, Inc. — Oceanside, California, United States
• Miami Dermatology And Laser Institute — Miami, Florida, United States
• Bioclinical Research Alliance Inc. — Miami, Florida, United States
• Forcare Clinical Research Inc — Tampa, Florida, United States
• Southeast Dermatology Specialists — Douglasville, Georgia, United States
• Arlington Dermatology — Rolling Meadows, Illinois, United States
• Skin Sciences, PLLC — Louisville, Kentucky, United States
• Qualmedica Research — Owensboro, Kentucky, United States
• DermAssociates, PC — Rockville, Maryland, United States
• Metro Boston Clinical Partners — Brighton, Massachusetts, United States
• ActivMed Practices and Research — Methuen, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Great Lakes Research Group — Bay City, Michigan, United States
• The Derm Institute of West Michigan — Caledonia, Michigan, United States
• Hamzavi Dermatology — Canton, Michigan, United States
• Somerset Skin Centre — Troy, Michigan, United States
• Cleaver Dermatology — Kirksville, Missouri, United States
• Bexley dermatology research — Bexley, Ohio, United States
• Essential Medical Research — Tulsa, Oklahoma, United States
• Alliance Dermatology and MOHS Center P C — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.